Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
University of North Carolina at Chapel Hill · Lunenfeld-Tanenbaum Research Institute · +1 more institution
Abstract
Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor (GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl peptidase-4 (DPP-4) promotes glycemic reduction for the treatment of type 2 diabetes mellitus by glucose-dependent control of insulin and glucagon secretion. GLP-1R agonists also decelerate gastric emptying, reduce body weight by reduction of food intake and lower circulating lipoproteins, inflammation, and systolic blood pressure. Preclinical studies demonstrate that both GLP-1R agonists and DPP-4 inhibitors exhibit cardioprotective actions in animal models of myocardial ischemia and ventricular dysfunction through incompletely…
Citation impact
- FWCI
- 38.80
- Percentile
- 100%
- References
- 171
Authors
5- MAMichael A. NauckCorresponding
University of North Carolina at Chapel Hill, Lunenfeld-Tanenbaum Research Institute, St. Josef-Hospital
- JJJuris J. Meier
University of North Carolina at Chapel Hill, Lunenfeld-Tanenbaum Research Institute, St. Josef-Hospital
- MAMatthew A. Cavender
University of North Carolina at Chapel Hill, Lunenfeld-Tanenbaum Research Institute, St. Josef-Hospital
- MAMirna Abd El Aziz
University of North Carolina at Chapel Hill, Lunenfeld-Tanenbaum Research Institute, St. Josef-Hospital
- DJDaniel J. Drucker
University of North Carolina at Chapel Hill, Lunenfeld-Tanenbaum Research Institute, St. Josef-Hospital
Topics & keywords
- Medicine
- Semaglutide
- Lixisenatide
- Alogliptin
- Saxagliptin
- Liraglutide
- Glucagon-like peptide 1 receptor
- Internal medicine